Pegdinetanib is a synthetic compound classified as a monoclonal antibody fragment, specifically designed for therapeutic applications. It is primarily known for its role as an anti-cancer agent, targeting the vascular endothelial growth factor (VEGF) pathway, which is crucial for tumor angiogenesis. The substance is characterized by its pegylation, a process that involves the attachment of polyethylene glycol (PEG) chains, enhancing its solubility, stability, and half-life in biological systems. This modification allows for reduced immunogenicity and improved pharmacokinetics. Pegdinetanib has been investigated for its efficacy in treating various malignancies, particularly those associated with abnormal blood vessel growth. Its mechanism of action involves inhibiting the binding of VEGF to its receptors, thereby disrupting the signaling pathways that promote tumor growth and metastasis. As with many therapeutic agents, the safety profile and potential side effects are critical considerations in its clinical use, necessitating thorough evaluation in clinical trials. Overall, Pegdinetanib represents a targeted approach in cancer therapy, leveraging the principles of molecular biology and biochemistry.

Pegdinetanib

906450-24-6: Pegdinetanib is a synthetic compound classified as a monoclonal antibody fragment, specifically designed for therapeutic applications. It is primarily known for its role as an anti-cancer agent, targeting the vascular endothelial growth factor (VEGF) pathway, which is crucial for tumor angiogenesis. The substance is characterized by its pegylation, a process that involves the attachment of polyethylene glycol (PEG) chains, enhancing its solubility, stability, and half-life in biological systems. This modification allows for reduced immunogenicity and improved pharmacokinetics. Pegdinetanib has been investigated for its efficacy in treating various malignancies, particularly those associated with abnormal blood vessel growth. Its mechanism of action involves inhibiting the binding of VEGF to its receptors, thereby disrupting the signaling pathways that promote tumor growth and metastasis. As with many therapeutic agents, the safety profile and potential side effects are critical considerations in its clinical use, necessitating thorough evaluation in clinical trials. Overall, Pegdinetanib represents a targeted approach in cancer therapy, leveraging the principles of molecular biology and biochemistry.

<p>Pegdinetanib (BMS-844203; CT-322) selectively inhibits VEGFR-2 with Kd/IC50 of 11/16 nM (human) and 250/240 nM (murine); no activity on VEGFR-1/3; anti-tumor.</p>

CAS 906450-24-6

Pegdinetanib

Pegdinetanib

Ref: TM-T77148